JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Organon & Co

Cerrado

SectorSalud

6.64 -5.68

Resumen

Variación precio

24h

Actual

Mínimo

6.39

Máximo

7

Métricas clave

By Trading Economics

Ingresos

-174M

-87M

Ventas

81M

1.6B

P/B

Media del Sector

3.435

37.461

BPA

1

Rentabilidad por dividendo

9.27

Margen de beneficio

-5.443

Empleados

10,000

EBITDA

124M

449M

Recomendaciones

By TipRanks

Recomendaciones

Vender

Estimación a 12 meses

+3.71% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

9.27%

2.33%

Próximas Ganancias

30 oct 2025

Fecha Próximo Dividendo

11 dic 2025

Próxima Fecha de Ex Dividendo

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-101M

2.4B

Apertura anterior

12.32

Cierre anterior

6.64

Noticias sobre sentimiento de mercado

By Acuity

42%

58%

131 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Organon & Co Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2025, 23:50 UTC

Acciones populares

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct 2025, 23:25 UTC

Ganancias

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct 2025, 23:18 UTC

Ganancias

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct 2025, 22:20 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct 2025, 22:13 UTC

Ganancias

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct 2025, 21:38 UTC

Ganancias

Correction to Visa Sales Jump Article

28 oct 2025, 21:17 UTC

Ganancias

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct 2025, 21:07 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct 2025, 21:02 UTC

Ganancias

Mondelez Tempers Outlook as Costs Rise

28 oct 2025, 23:51 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct 2025, 23:02 UTC

Ganancias

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct 2025, 23:01 UTC

Ganancias

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct 2025, 22:46 UTC

Ganancias

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct 2025, 22:45 UTC

Ganancias

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct 2025, 22:44 UTC

Ganancias

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct 2025, 22:43 UTC

Ganancias

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct 2025, 22:42 UTC

Ganancias

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct 2025, 22:20 UTC

Ganancias

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct 2025, 22:02 UTC

Ganancias

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct 2025, 21:20 UTC

Ganancias

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct 2025, 21:19 UTC

Ganancias

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct 2025, 21:18 UTC

Ganancias

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparación entre iguales

Cambio de precio

Organon & Co Esperado

Precio Objetivo

By TipRanks

3.71% repunte

Estimación a 12 meses

Media 9.5 USD  3.71%

Máximo 14 USD

Mínimo 5 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Organon & Co Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

2 ratings

0

Comprar

0

Mantener

2

Vender

Puntuación técnica

By Trading Central

8.53 / 9.18Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

131 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat